Abcellera Biologics Non Current Liabilities Total Over Time
| ABCL Stock | USD 2.95 0.19 6.88% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Abcellera Biologics Performance and Abcellera Biologics Correlation. Abcellera |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.61) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.01) | Return On Assets (0.13) |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Non Current Liabilities Total Analysis
Compare Abcellera Biologics and related stocks such as CohBar Inc, Hepion Pharmaceuticals, and Rain Therapeutics Non Current Liabilities Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HEPA | 3.6 K | 3.6 K | 3.6 K | 4.5 M | 4.5 M | 1.5 M | 6.7 M | 6.4 M | 3.4 M | 3.4 M | 3.5 M | 2.4 M | 2.5 M | 5.5 M | 4 M |
| KRYS | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 0.0 | 294 K | 2.8 M | 3.3 M | 7 M | 7.4 M | 6.6 M | 4 M |
| CVAC | 65.4 M | 65.4 M | 65.4 M | 65.4 M | 65.4 M | 65.4 M | 65.4 M | 65.4 M | 65.4 M | 145.3 M | 552.4 M | 112 M | 171 M | 84.9 M | 150.8 M |
| VIR | 308 M | 308 M | 308 M | 308 M | 308 M | 308 M | 308 M | 308 M | 330.9 M | 28.9 M | 102.8 M | 181.2 M | 213.1 M | 153.4 M | 150.7 M |
| PTCT | 239.6 M | 239.6 M | 4.1 M | 2.2 M | 2.3 M | 96.7 M | 100.1 M | 153.2 M | 601.7 M | 793.6 M | 1.4 B | 1.2 B | 1.6 B | 2.1 B | 2.2 B |
| SRPT | 3.1 M | 2.8 M | 2.4 M | 8.4 M | 10.5 M | 21.1 M | 12 M | 430.4 M | 436.1 M | 739.9 M | 1.8 B | 1.8 B | 2.1 B | 1.8 B | 1.8 B |
| IOVA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 230 K | 6.6 M | 57.1 M | 66.5 M | 84.4 M | 85.4 M | 89.7 M |
| MDGL | 1.2 M | 12.4 M | 4.5 M | 13.9 M | 4.7 M | 0.0 | 0.0 | 0.0 | 0.0 | 361 K | 468 K | 387 K | 49.3 M | 116.7 M | 122.5 M |
Abcellera Biologics and related stocks such as CohBar Inc, Hepion Pharmaceuticals, and Rain Therapeutics Non Current Liabilities Total description
My Equities
My Current Equities and Potential Positions
| Abcellera Biologics | ABCL |
| Classification | Biotech |
| Location | British Columbia; Canada |
| Exchange | NASDAQ Exchange |
USD 2.95
Check out Abcellera Biologics Performance and Abcellera Biologics Correlation. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Abcellera Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.